Associate Director, US Virology Strategy and Policy - Government Affairs at Gilead Sciences

Foster City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Deep knowledge of U.S. federal and state healthcare policy (Medicare and Medicaid)
Deep knowledge of the U.S. HIV/AIDS landscape
Understanding of the pharmaceutical industry (preferred)
Ten years of experience
Strong leadership, partnership, and teamwork skills

Responsibilities

Report to ED of Virology Strategy and Policy and serve as a member of the virology strategy and policy team
Support and help manage the annual strategic planning process, resulting in comprehensive government affairs strategies that shape the US public policy environment for existing and pipeline products in virology, primarily HIV
Collaborate with members across GA teams to define and evolve Gilead’s U.S. virology policy positions in support of corporate mission to maintain patient-provider choice and access to innovative HIV treatment and prevention medicines
Support the execution of these strategies by GA organization and collaborate with cross-functional partners on key workstreams
Anticipate trends in the external environment that will impact HIV markets and develop plans to address areas of concern
Develop resources for internal and external stakeholders, including talking points, issue briefs, one-pagers, reports, and presentations, that outline policy positions, implications, arguments, and key messages
Support engagement with influential third-party policy organizations, including health care policy experts, policy research organizations, and aligned patient advocacy groups
Conduct policy analysis and research
Build evidence-based messaging and argumentation
Inform and develop policy and advocacy materials for internal and external audiences
Serve as a resource to U.S. government teams on policies that impact patient access to Gilead’s innovative virology medicines, with an emphasis on the HIV portfolio

Skills

Policy Analysis

Government Affairs

Public Policy

Legislative Strategy

Regulatory Affairs

Advocacy

Virology

Stakeholder Engagement

Research

Strategy Development

Messaging

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters

1987Year Founded

$15,873.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.

Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.

Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.

Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.

Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.

Investment in digital health technologies enhances Gilead's R&D and patient engagement.

Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI

Try Jobo Free